Indaptus Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the bottom line, with a net loss of $1.8M and EPS of -$0.02, compared to the expected loss of $4.87M and EPS of -$1.57. The variance was driven by aggressive cost-cutting measures, including an 83% YoY reduction in R&D and a 37% YoY decrease in G&A expenses following the discontinuation of the Decoy20 clinical program. A June private placement provided $12.0M in gross proceeds, strengthening the cash position to $11.6M (including short-term investments) as the company pivots toward a strategic review of its Decoy platform and potential M&A opportunities.